Related Experiment Video
Updated: Jun 22, 2026
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
Four novel PDHA1 mutations in pyruvate dehydrogenase deficiency
E Ostergaard1, L Birk Moller, H Serap Kalkanoglu-Sivri
1Department of Clinical Genetics 4062, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Denmark. elsebet.oestergaard@rh.regionh.dk
Journal of Inherited Metabolic Disease
|June 12, 2009
Summary
Researchers identified four new mutations in the PDHA1 gene causing pyruvate dehydrogenase deficiency. This genetic disorder impacts cellular energy production, leading to neurological and metabolic symptoms in affected individuals.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Pyruvate dehydrogenase (PDH) complex is crucial for mitochondrial energy metabolism.
- PDH deficiency is a genetic disorder resulting from mutations in PDHA1, PDHB, or DLD genes.
Observation:
- Four novel PDHA1 mutations were identified in patients with pyruvate dehydrogenase deficiency.
- PDH activity was reduced in fibroblasts from all four patients (16-52% of control).
- Identified mutations include two missense, one in-frame deletion, and one 65 bp duplication.
Findings:
- cDNA analysis revealed a small amount of normal transcript in the 65 bp duplication case, potentially explaining patient survival.
- Western blot analysis showed decreased E(1)α and E(1)β protein levels for the duplication and one missense mutation.
- The other two mutations were associated with normal protein amounts.
Implications:
- This study expands the known spectrum of PDHA1 mutations, contributing to the understanding of PDH deficiency.
- The findings aid in correlating genotype with phenotype in PDH deficiency, particularly the infantile form.
- Further research can explore genotype-phenotype correlations and therapeutic strategies for PDH deficiency.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Pyruvate Oxidation
After glycolysis, the charged pyruvate molecules enter the mitochondria via active transport and undergo three enzymatic reactions. These reactions ensure that pyruvate can enter the next metabolic pathway so that energy stored in the pyruvate molecules can be harnessed by the cells.
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...